Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study.

ABSTRACT:

Objectives

To investigate the eligibility of a real-world neovascular age-related macular degeneration (nAMD) population for the TENAYA and LUCERNE trials (testing faricimab), and to compare the eligible real-world patients to trial participants.

Design, settings and participants

In this retrospective cross-sectional study, we used data from the Swedish Macula Registry (SMR) between 1 January 2017 and 31 December 2020. Persons were eligible if they fulfilled the main inclusion criteria in TENAYA and LUCERNE: (1) nAMD diagnosis, (2) treatment naïve, (3) ≥50 years and (4) best-corrected visual acuity (BCVA) of 78-24 letters.

Main outcome measures

Characteristics at the original visit of the eligible SMR population and baseline data from the clinical trials were compared

SUBMITTER: Jern I 

PROVIDER: S-EPMC9472139 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature